The revenue beat was driven by product sales growth, but the company's guidance implies a significant H2 slowdown to hit the $78M-$83M full-year target. Monitor Q3 and Q4 revenue trends for Elfabrio and Elelyso to assess whether the guidance is achievable without additional milestones.
Drugs in focus
PLX drug pipeline →PRX-115
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- If Phase 2 data in H2 2027 is positive, a Phase 3 program would follow, meaning potential FDA approval/commercialization is likely several years away, likely 2029-2031 at the earliest.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 2 RELEASE study (NCT07280156) topline results, expected in the second half of 2027. Positive data showing sustained uric acid reduction with infrequent dosing could significantly de-risk the program and support a path to registration. Negative or equivocal results would likely weigh heavily on the stock given PRX-115's importance as the lead pipeline asset. Interim data or updates at medical conferences in the interim could also move the stock.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 12 $2.62entry
- T+1 · 3mo ago −9.92%α −10.62% · $2.36
- T+5 · 3mo ago −10.31%α −9.86% · $2.35
- T+20 · 2mo ago +4.20%α +6.10% · $2.73
- T+60 · 12d ago −4.20%α +0.91% · $2.51
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Protalix reported Q2 2026 revenue of $19.9M, beating the $12.9M consensus, and EPS of $0.05, beating the $-0.01 consensus. Revenue growth was driven by higher Elfabrio sales to Chiesi and Fiocruz, partially offset by lower Pfizer purchases. The company reiterated full-year 2026 revenue guidance of $78M-$83M.
Key Financial Metrics
Key Facts
- Q2 2026 total revenue of $19.9M, up from $15.7M in Q2 2025
- Q2 2026 net income of $3.8M ($0.05 per share) vs net income of $164K ($0.00) in Q2 2025
- Revenues from selling goods were $19.8M in Q2 2026, up $4.4M from Q2 2025, driven by higher Elfabrio sales to Chiesi and Fiocruz
- Revenues from license and R&D services were $68K in Q2 2026 vs $218K in Q2 2025
- Cash, cash equivalents, and short-term bank deposits were $40.7M as of June 30, 2026
- Full-year 2026 revenue guidance reiterated at $78.0M-$83.0M, including the $25.0M Chiesi milestone
- PRX-115 Phase 2 study continues enrollment; top-line results expected in H2 2027
- USPTO issued a 5-year Patent Term Extension for Elfabrio, extending U.S. expiration to November 17, 2035
Financial Impact
Q2 2026 revenue of $19.9M beat consensus of $12.9M by 54%; EPS of $0.05 beat consensus of $-0.01
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Revenues from selling goods | $19.8M | +28.4% |
| Revenues from license and R&D services | $68.0K | -68.8% |
Risk Factors
- Full-year guidance implies H2 2026 revenue of roughly $24M-$29M, a sharp drop from the $53.6M in H1, suggesting reliance on the non-recurring $25M milestone
- Pfizer purchases remain lower due to prior-year manufacturing issues, creating revenue concentration risk with Chiesi and Fiocruz
- PRX-115 Phase 2 data not expected until H2 2027, leaving the pipeline without near-term catalysts
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-094433 |
| Document: plx-20260812x8k.htm | 0001104659-26-094433 |
| Document: 0001104659-26-094433-index-headers.html | 0001104659-26-094433 |
| Document: 0001104659-26-094433-index.html | 0001104659-26-094433 |
| Document: 0001104659-26-094433.txt | 0001104659-26-094433 |
| 8-K Data (Synthetic) | 0001104659-26-094433 |
Track record
3 reports on PLX
Filters
- Nov 10, 20266d ago 8-K Neutral 4/10 Entry $2.86 Now $3.03 +5.94% settles Dec 9
- Oct 15, 20264w ago SC 13G Neutral 3/10 Entry $2.70 to $2.96 Now $3.03 +12.22% ▲ +9.63% +11.53% vs SPY
- Aug 12, 202613w ago 8-K Neutral 5/10 Viewing Entry $2.62 to $2.73 Now $3.03 +15.65% ▲ +4.20% +6.10% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers